Researchers from the University of Michigan Health Rogel Cancer Center have developed a monitoring system using a research genetics program to trigger alerts about cancer patients suspected to have the DPYD gene variant.
|
Everyone has a story. And those stories help show the different influences on each person’s life, helping to build empathy, challenge stereotypes and create a more inclusive environment. That’s the basis of a new DEI initiative the Rogel Oncology Clinical Trials Support Unit, or OCTSU, has started. DEI Storytelling gives a platform for team members to share their personal journey, anecdotes or reflections, with an emphasis on topics that may not be widely understood by all staff.
|
Rogel Cancer Center faculty and trainees will lead more than three dozen presentations, posters and moderated sessions at the American Society of Hematology 2023 annual meeting. This year’s meeting will be held in-person and virtually in San Diego, California. Find a list of U-M presenters and other resources for attendees.
|
|
|
|
For men with a type of low-risk early prostate cancer, surveillance can be an option over immediate treatment. To help providers and patients make more informed decisions about safely choosing surveillance, Rogel Cancer Center researcher Simpa Salami, M.D., M.P.H., received a $1.14 million grant from the National Cancer Institute to answer lingering questions about the biology of these early prostate cancers.
|
New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.
|
|
|
|
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a study finds. For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly.
|
|
|
MENU